Appointments: ThermiGen, ReForm Biologics, Hookipa Biotech and Faron

Karolinska Development AB has appointed current deputy CEO and chief investment officer Viktor Drvota CEO, following the resignation of current CEO, Jim Van heusden. Drvota’s appointment will be effective from June 1, 2017 and heusden’s resignation from the end of October, 2017. The company has also announced the resignation of its chair, Bo Jesper Hansen, who will not be standing for re-election at the 2017 annual general meeting. Heusden will be pursuing new opportunities, having joined Karolinska to oversee a major strategic turnaround of the organization. Drvota joined the company in February, 2016 as chief investment officer and was promoted to deputy CEO in March, 2017. He has over 15 years’ life science investment experience and before Karolinska he worked at SEB Venture Capital, where he was head of life science and a senior investment manager.

Vladimir Paul-Blanc had been appointed president and general manager of ThermiGen LLC, an Almirall SA business. Paul-Blanc brings more than 13 years’ experience in general management positions to the company and most recently, he was general manager for Solta Medical Inc